Executive Summary
Across 36 DEF 14A proxy statements filed around April 14, 2026, overarching themes include routine elections of directors (e.g., 100% board nominees in most cases), advisory say-on-pay votes, auditor ratifications (e.g., Deloitte, KPMG, E&Y dominant), and frequent amendments to equity incentive plans (e.g., increases in authorized shares for 10+ firms like EOSE, NSP, INSPIRE, ARBT) signaling aggressive talent retention amid 2025's mixed performance. Period-over-period trends show limited but telling data: bullish outliers like Equity Residential's 2.6% YoY Normalized FFO growth ($3.99/share), MyRisk volumes +10% at Myriad Genetics, and Brighthouse's audit fees +0.2% (stable), contrasted by bearish Mattel net sales -1% YoY, Flowers Foods' GAAP EPS $0.40 vs adjusted $1.09 (wide gap), and REGENXBIO's FDA clinical hold (Jan 2026) + CRL (Feb 2026). Sentiment is neutral-dominant (26/36), positive in 5 (EQR, MYGN, NRDS, ADT, TBI), mixed in 5; no widespread insider selling, with ownership guidelines met (e.g., Brighthouse directors hold 2,837-4,556 RSUs, no vested sales). Portfolio-level patterns: REITs outperform on growth (EQR top-quartile NOI +2.2%), biotechs face regulatory hurdles (3/5 mixed), consumer flat/declining; capital returns strong in EQR ($1.38B dividends/buybacks) and TrueBlue (19% share reduction via 6.7M repurchases). Critical implications: Annual meetings (May-June 2026 cluster) as catalysts for comp backlash or plan approvals; watch dilutive share hikes and SPAC liquidation risks for near-term volatility.
Tracking the trend? Catch up on the prior US Executive Compensation Proxy SEC Filings digest from April 07, 2026.
Investment Signals(12)
- Equity Residential↓(BULLISH)▲
Normalized FFO +2.6% YoY to $3.99/share, same-store revenue +2.6% and NOI +2.2% (top-quartile peers), $300M buybacks + $1.38B total returns
- Myriad Genetics↓(BULLISH)▲
2025 revenue $824.5M, MyRisk volumes +10% YoY, GeneSight +8% H2'25 post-recovery, 2026 launches AI Prolaris + Precise MRD ($20B TAM)
- TrueBlue↓(BULLISH)▲
2025 revenue $1.6B, Adjusted EBITDA $11.8M, repurchased 6.7M shares (19% outstanding reduction over 5yrs), acquired Healthcare Staffing Pros
- ADT↓(BULLISH)▲
2025 strategic wins (ADT+ expansion, Origin AI acquisition), governance upgrades (board declassification, independent committees), no performance declines
- NerdWallet↓(BULLISH)▲
2025 expansions (wealth mgmt, debt consol, performance marketing), Oct 2024 Next Door Lending acquisition, organic channel momentum
- Brighthouse Financial↓(BULLISH)▲
All directors met ownership guidelines (4x retainer, 2,837-4,556 RSUs), no vested equity sales as of record date, audit fees +0.2% YoY to $13.694M
- Flowers Foods↓(BEARISH)▲
FY25 (53-wk) net sales $5.256B, adj EBITDA $535.2M, long-term guidance 1-2% sales/4-6% EBITDA/7-9% EPS growth (ex-M&A) but GAAP EPS $0.40 vs adj $1.09
- Mattel↓(BEARISH)▲
2025 net sales -1% YoY (flat gross billings), North America declines offset by Intl/Vehicles growth amid trade uncertainty
- REGENXBIO↓(BEARISH)▲
2025 highlights ($110M upfront Nippon, $150M royalty bond, $200M AbbVie milestones, $240.9M cash) offset by RGX-121 FDA hold Jan'26 + CRL Feb'26
- Drugs Made In America↓(BEARISH)▲
SPAC non-binding LOI but no deal certainty, extension requires sponsor $300K/mo deposits or risk liquidation/redemption at ~$10.52/share
- Eos Energy↓(BEARISH)▲
Series B prefs appoint 3/9 directors, cash $240.9M'25 but proposing 600M to 800M authorized share increase + incentive plan amendment
- Enveric Biosciences↓(BEARISH)▲
Proposing 100M to 5B authorized shares + reverse split extension (1:5-50) for Nasdaq compliance/capital raise flexibility
Risk Flags(10)
- REGENXBIO/FDA Regulatory↓[HIGH RISK]▼
RGX-121 BLA priority review PDUFA Feb 8'26 after CRL Feb'26 + clinical hold Jan'26 (SAE in RGX-111), delays ABBV-RGX-314 pipeline
- Drugs Made In America/SPAC Liquidation↓[HIGH RISK]▼
EGM Apr 27'26 for deadline extension to Apr'27 or face full redemption/liquidation Apr 29'26, sponsor interests misaligned
- Eos Energy/Dilution↓[MEDIUM RISK]▼
Proposal to hike authorized common from 600M to 800M shares + amend 2020 Incentive Plan, amid Series B control of 3 board seats
- Enveric Biosciences/Dilution↓[MEDIUM RISK]▼
Extend reverse split (1:5-50) + authorized shares 100M to 5B (from Dec'25 approval expiring Dec'26), only 1.89M shares outstanding
- Flowers Foods/GAAP Discrepancy↓[MEDIUM RISK]▼
FY25 GAAP net income $83.8M/EPS $0.40 vs adj $231.6M/$1.09 (149% gap), heavy non-GAAP reliance amid 53-wk sales $5.256B
- Mattel/Sales Decline↓[MEDIUM RISK]▼
2025 net sales -1% YoY despite Vehicles/Challenger growth, U.S. trade uncertainties weigh on North America
- Strata Critical Medical/Board Turnover↓[MEDIUM RISK]▼
Eric Affeldt not re-elected, Susan Lyne resigning at May 28'26 meeting, post-passenger biz sale to Joby Aero Aug'25
- Bluerock Homes/EGC Status↓[LOW RISK]▼
Emerging growth co ceases JOBS Act benefits end FY27, externally managed REIT with low shares outstanding (4.1M voting)
- National Presto/Family Control↓[LOW RISK]▼
Cohen family voting trust (1.67M shares, Ms. Cohen sole trustee to 2044), owns 26% with officers/directors
- Franklin BSP/Dilution↓[LOW RISK]▼
Authorize board to issue 25% outstanding common below NAV, 138.9M common + 77.5K prefs (as-converted voting)
Opportunities(10)
- Equity Residential/Operational Excellence↓(OPPORTUNITY)◆
Historic low same-store turnover 40.2%, expenses +3.7% YoY (modest), $1.1B dispositions funded $637M acquisitions
- Myriad Genetics/Product Launches↓(OPPORTUNITY)◆
Cancer Care Continuum strategy, 2026 AI-enhanced Prolaris + Precise MRD (1ppm ctDNA detection, $20B TAM), NPS 72.5
- TrueBlue/Market Leadership↓(OPPORTUNITY)◆
Top-5 U.S. industrial staffing (50 states), 290K+ placements/50K+ clients, 19% share reduction via buybacks
- NerdWallet/Strategic Expansion↓(OPPORTUNITY)◆
2025 hands-on services (wealth mgmt/debt consol), new channels + vertical integrations, Oct'24 mortgage brokerage buy
- ADT/Governance + Innovation↓(OPPORTUNITY)◆
Board 8/12 independent (post-declassification), AI investments + ADT+ platform scaling via 12K pros
- Brighthouse Financial/Stability↓(OPPORTUNITY)◆
Pending merger vests pre-Nov'25 RSUs, Deloitte partner rotation 2027, sustainability/human capital oversight
- Celsius Holdings/Ownership Stability↓(OPPORTUNITY)◆
Insiders/directors own 2.33% (6M shares), top 5% holders (Chau 8.97%, Alani 8.74%) unchanged
- LeMaitre Vascular/Governance↓(OPPORTUNITY)◆
No delinquent Sec 16(a) reports FY25, strong attendance, available stockholder list pre-Jun 2'26 meeting
- Insperity/Incentive Alignment↓(OPPORTUNITY)◆
Second amendment to Incentive Plan, 38.2M shares outstanding, all proposals non-routine signaling engagement
- SPS Commerce/Growth Setup↓(OPPORTUNITY)◆
Virtual meeting May 28'26, 401(k) voting deadline May 22, no PoP declines noted amid supply chain software demand
Sector Themes(6)
- REIT Outperformance(REIT STRENGTH)◆
6/36 filings (EQR, AIREIT, ZARE, CNSREIT, BHM, FBCC) show stable governance/low turnover; EQR +2.6% FFO/NOI top-quartile implies sector resilience amid rate uncertainty
- Biotech Regulatory Hurdles(BIOTECH MIXED)◆
4 firms (RGNX mixed FDA holds/CRL, ARBT/ENVB share hikes for capital, MYGN +10% volumes outlier); mixed sentiment avg, watch clinical catalysts
- Consumer Goods Stagnation(CONSUMER WEAKNESS)◆
SPWH/CELH neutral ownership, MAT -1% sales, FLO GAAP weak (5/36); flat YoY trends vs broader mkt, trade/inflation drags
- Financials Stability(FINANCIALS NEUTRAL)◆
Brighthouse +0.2% audit fees/ownership met, Northrim/CalBanCorp/CUBI governance focus (18-13 mtgs), no NIM declines; low volatility
- Comp Plan Expansions Prevalent(TALENT RETENTION TREND)◆
12/36 seek share increases/amendments (EOSE +33%, ENVB +4900%, NSP/ARBT/APCX etc.), signals talent war but dilution risk in small caps
- Virtual Meeting Dominance(GOVERNANCE SHIFT)◆
28/36 virtual (e.g., SPWH/NRIM/NABL May28-Jun3), quorum 50%+ shares; eases access but limits physical scrutiny, deadlines cluster May24-27
Watch List(8)
Vote Apr 27'26 on SPAC deadline to Apr'27, monitor redemptions (capped 15%) + sponsor deposits vs liquidation risk Apr29 [Apr 27, 2026]
Post-RGX-121 hold Jan'26/CRL Feb'26, track ABBV-RGX-314/RGX-202 progress + May29'26 meeting say-on-pay [May 29, 2026]
Top metrics + capital returns, watch say-on-pay + any buyback updates at Jun18'26 virtual meeting [Jun 18, 2026]
600M-800M authorized + plan amendment at Jun3'26 meeting, Series B board control, dilution vs $240.9M cash [Jun 3, 2026]
Wide GAAP/adj gap + LT guidance, monitor advisory vote backlash at May29'26 meeting [May 29, 2026]
5B authorized + R/S extension for Nasdaq, low 1.89M float, post-Dec'25 approvals expiring Dec'26 [TBD 2026]
2 directors out at May28'26, post-rebrand/sale, assess continuity [May 28, 2026]
AI Prolaris/Precise MRD rollout into $20B TAM, volume momentum +1.5M tests'25 [Ongoing 2026]
Filing Analyses(36)
14-04-2026
Sportsman’s Warehouse Holdings, Inc. (SPWH) has filed its DEF 14A Proxy Statement for the 2026 Annual Meeting of Stockholders, to be held virtually on May 27, 2026, at 8:00 a.m. Mountain Time, with a record date of April 2, 2026. Key proposals include electing six director nominees, advisory approval of named executive officer compensation, approving a second amendment to the Amended and Restated 2019 Performance Incentive Plan to increase shares available for grants, ratifying Grant Thornton LLP as independent auditors for fiscal year 2026, and an advisory vote on the frequency of future say-on-pay votes (Board recommends 1 year). No specific financial performance metrics or period-over-period comparisons are provided in the filing excerpt.
- ·Annual Meeting accessible via www.virtualshareholdermeeting.com/SPWH2026 using control number from proxy card.
- ·Proxy materials and 2025 Form 10-K for fiscal year ended January 31, 2026, mailed on or about April 14, 2026.
- ·Principal executive offices: 1475 West 9000 South, Suite A, West Jordan, Utah 84088.
- ·Stockholder list available for examination 10 days prior to meeting at principal offices.
14-04-2026
Brighthouse Financial's 2026 Proxy Statement outlines director governance practices, including stock ownership guidelines met by all long-serving directors with unvested RSUs held at 4,556 for Chairman Chaplin and 2,837 each for the other seven directors as of December 31, 2025; it notes that a pending merger could trigger immediate vesting of pre-November 6, 2025 RSUs. Proposal 2 seeks stockholder ratification of Deloitte & Touche LLP as independent auditor for 2026, with audit fees nearly flat at $13.694M in 2025 versus $13.666M in 2024 (up 0.2%), while audit-related fees rose sharply 82% to $0.902M and total fees increased 3.4% to $14.78M. The proxy also covers sustainability initiatives overseen by board committees and human capital management rooted in core values.
- ·Independent Directors expected to hold shares equal to at least 4x equity portion of annual retainer, achievable within 5 years of guidelines effective date (Jan 1, 2018) or service start.
- ·Directors required to retain 50% of net shares from vesting until guidelines met; no Director sold vested equity as of Record Date.
- ·Current Deloitte lead partner engaged since 2022 audit, eligible through 2026; new partner in 2027 per rotation rules.
14-04-2026
ARES Industrial Real Estate Income Trust Inc. (AIREIT) has issued a proxy statement for its annual stockholder meeting on June 24, 2026, at the Tabor Center in Denver, CO, with a record date of April 8, 2026, and approximately 279,427,586 shares of common stock outstanding. Stockholders will vote on electing eight directors (all current nominees) and ratifying KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026; the Board recommends voting FOR both proposals. No other matters are anticipated, with voting results to be reported in a Form 8-K within four business days post-meeting.
- ·Quorum requires holders of 50% of outstanding shares present in person or by proxy.
- ·Director election requires majority of shares represented at the meeting; ratification of auditors requires majority of votes cast.
- ·Annual Report on Form 10-K for year ended December 31, 2025, filed with SEC on March 6, 2026, available on company website or SEC.gov.
- ·Proxy solicitation expenses borne by the Company, including reimbursement to brokers for forwarding materials.
14-04-2026
Ares Real Estate Income Trust Inc. (ZARE) has issued a proxy statement for its Annual Meeting on June 24, 2026, at the Tabor Center in Denver, CO, seeking shareholder approval to elect seven directors (David A. Roth, Jay W. Glaubach, Andrew E. Holm, Charles B. Duke, John P. Woodberry, Bryan B. Sanchez, and Paula Schaefer) and ratify KPMG LLP as independent auditors for the fiscal year ending December 31, 2026. As of the record date of April 8, 2026, 189,571,904 shares of common stock are outstanding, requiring a quorum of 50% for the meeting. The Board unanimously recommends voting FOR both proposals, with no other matters anticipated.
- ·Board consists of seven directors, four independent (Charles B. Duke, Bryan B. Sanchez, John P. Woodberry, Paula Schaefer).
- ·Election requires majority of shares represented at meeting; ratification requires majority of votes cast.
- ·Annual Report on Form 10-K for year ended December 31, 2025 filed March 6, 2026, available on www.areswms.com/solutions/areit or www.sec.gov.
- ·Voting results to be reported in Form 8-K within four business days post-meeting.
14-04-2026
REGENXBIO Inc.'s DEF 14A Proxy Statement for the May 29, 2026 Annual Meeting seeks stockholder approval to elect three Class II directors (Jean Bennett, A.N. 'Jerry' Karabelas, and Daniel Tassé), ratify PricewaterhouseCoopers LLP as auditors for 2026, approve an advisory vote on executive compensation, and authorize stock option exchanges for non-executive and executive employees to replace underwater options. 2025 business highlights include clinical progress in ABBV-RGX-314 and RGX-202 programs, a $110.0 million upfront payment from Nippon Shinyaku, $150 million from a royalty bond (up to $250 million), AbbVie milestone amendments worth $200 million, and $240.9 million in cash at year-end; however, the RGX-121 program encountered an FDA clinical hold in January 2026 and a Complete Response Letter in February 2026.
- ·Record date for Annual Meeting: April 1, 2026
- ·FDA priority review for RGX-121 BLA granted May 2025 with initial PDUFA date November 9, 2025 (revised to February 8, 2026)
- ·FDA clinical hold on RGX-121 program in January 2026 due to serious adverse event in RGX-111 trial
- ·Board nominees to serve until 2029 annual meeting
- ·Engaged with top 25 stockholders representing 68% of outstanding common stock in 2025
14-04-2026
Loar Holdings Inc. (LOAR) has issued a proxy statement for its 2026 Annual Meeting of Stockholders on June 2, 2026, virtually at www.virtualshareholdermeeting.com/LOAR2026, with a record date of April 6, 2026. Shareholders will vote on electing three Class II directors (Raja Bobbili, Alison Bomberg, Margaret (Peg) McGetrick), ratifying Ernst & Young LLP as independent auditors for FY 2026, approving 2025 named executive officer compensation on an advisory basis, and the frequency of future say-on-pay votes (board recommends annually). No financial performance metrics or period-over-period comparisons are detailed in the filing.
- ·Voting recommendations: FOR all director nominees, FOR auditor ratification, FOR advisory approval of 2025 NEO compensation, ONE YEAR frequency.
- ·Proposals are non-routine except auditor ratification (routine, broker discretionary).
- ·Proxy materials available on or about April 13, 2026 via www.proxyvote.com.
14-04-2026
Insperity, Inc. (NSP) filed its DEF 14A proxy statement for the 2026 Annual Meeting of Stockholders on May 18, 2026, at its Kingwood, Texas headquarters, with a record date of April 6, 2026, and 38,169,182 shares of common stock outstanding. Stockholders will vote on electing four director nominees, an advisory 'say-on-pay' vote on executive compensation, approval of the Second Amendment to the Insperity, Inc. Incentive Plan, and ratification of Ernst & Young LLP as independent auditors for the year ending December 31, 2026. No financial performance metrics or period-over-period comparisons are provided in the filing excerpt.
- ·Meeting location: Auditorium in Centre I, 19001 Crescent Springs Drive, Kingwood, Texas 77339, at 1:30 p.m. Houston time.
- ·Voting standard for all proposals: Votes cast FOR must exceed votes cast AGAINST; Proposals 1-3 are non-routine (broker non-votes possible), Proposal 4 is routine.
- ·Quorum requires majority of outstanding shares present in person or by proxy.
14-04-2026
LeMaitre Vascular, Inc. filed its DEF 14A Proxy Statement on April 14, 2026, for the 2026 Annual Meeting of Stockholders on June 2, 2026, at 10:00 a.m. EDT in Burlington, Massachusetts. The meeting seeks to elect two Class II directors for three-year terms, approve by non-binding advisory vote the 2025 compensation of named executive officers, and ratify Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The record date is April 6, 2026, and proxy materials are available online at investorvote.com/LMAT.
- ·Annual Report on Form 10-K for the year ended December 31, 2025, available with proxy materials.
- ·Stockholder list available for examination 10 days prior to meeting via email to ir@lemaitre.com with proof of ownership.
- ·Meeting location: 32 Third Avenue, Burlington, Massachusetts 01803.
14-04-2026
N-able, Inc. (NABL) filed its DEF 14A proxy statement for the virtual annual stockholder meeting on May 28, 2026 at 9:00 a.m. ET, with proposals to elect three Class II directors, ratify PricewaterhouseCoopers LLP as independent auditors for the fiscal year ending December 31, 2026, and approve on a non-binding advisory basis the compensation of named executive officers. The record date is April 1, 2026, and proxy materials were distributed on or about April 14, 2026. The filing includes executive compensation disclosures for fiscal years 2021-2025 covering PEO and non-PEO NEOs, director compensation, and references to the 2025 Annual Report.
- ·Annual meeting held virtually at www.virtualshareholdermeeting.com/NABL2026
- ·Sponsors include Silver Lake Funds (Silver Lake Partners IV, L.P., Silver Lake Technology Investors IV, L.P., SLP Aurora Co-Invest, L.P.) and Thoma Bravo Funds (Thoma Bravo Fund XI, L.P., etc.)
14-04-2026
Northrim BanCorp, Inc. (NRIM) filed its DEF 14A proxy statement dated April 14, 2026, for the virtual 2026 Annual Shareholders’ Meeting on May 28, 2026, at 9 A.M. Alaska Daylight Time. Shareholders of record as of March 31, 2026, will vote on electing 12 directors, approving the First Amendment to the 2025 Stock Incentive Plan to include non-employee directors, an advisory vote on named executive officer compensation, and ratifying Baker Tilly US LLP as the independent auditor for fiscal 2026. The Board recommends voting 'FOR' all proposals, with 22,239,676 shares of common stock outstanding as of the record date.
- ·Record date for voting eligibility: March 31, 2026.
- ·Virtual meeting access requires 16-Digit Control Number from Notice or proxy card.
- ·Proxy materials and 2025 Annual Report/10-K available at www.northrim.com (Investor Relations) and www.proxyvote.com.
14-04-2026
SPS Commerce, Inc. filed its DEF 14A proxy statement on April 14, 2026, for the virtual 2026 Annual Meeting of Stockholders on May 28, 2026, at 8:00 a.m. Central Time. Key items include election of nine directors for one-year terms, ratification of KPMG LLP as independent auditor for the fiscal year ending December 31, 2026, and an advisory 'Say-on-Pay' vote on named executive officer compensation. The record date is March 30, 2026, with no financial performance metrics or period-over-period comparisons disclosed in the filing.
- ·Virtual meeting access: www.virtualshareholdermeeting.com/SPSC2026
- ·Voting deadlines: 11:59 p.m. ET on May 27, 2026 for direct shares; May 22, 2026 for 401(k) Plan shares
- ·Company address: 333 South Seventh Street, Suite 1000, Minneapolis, Minnesota 55402
14-04-2026
Celsius Holdings, Inc. (CELH) filed its DEF 14A Proxy Statement on April 14, 2026, for its 2026 annual meeting, disclosing beneficial ownership of common stock as of the Record Date with 256,896,075 shares outstanding. Management, executive officers, and directors collectively own 6,029,971 shares (2.33%), while major 5%+ shareholders include Chau Hoi Shuen Solina (23,040,969 shares, 8.97%), Alani Holdings, LLC (22,451,224 shares, 8.74%), and Deborah DeSantis (19,577,490 shares, 7.62%). No period-over-period changes in ownership or performance metrics are reported.
- ·Stockholder proposals for inclusion in 2027 Annual Meeting proxy materials due by December 15, 2026.
- ·Director nominations or business proposals for 2027 Annual Meeting must be received no earlier than January 28, 2027, and no later than February 27, 2027.
- ·Hans Melotte will serve out his term on the Board, expiring at the Annual Meeting.
- ·Several directors and executives own 0 shares: Christy Jacoby, Fletcher Previn, John Short.
14-04-2026
AppTech Payments Corp.'s DEF 14A proxy statement solicits votes for the 2026 Annual Meeting on May 28, 2026, including the election of two Class II directors: Albert L. Lord (Chairman) and Thomas J. DeRosa (President and CEO). Other proposals comprise advisory approval of named executive officer compensation, an advisory vote on the frequency of future say-on-pay votes, approval of the 2026 AppTech Equity Incentive Plan, and ratification of dbbmckennon LLC as independent auditors for the fiscal year ending December 31, 2026. The Board consists of five directors with a staggered structure, and no family relationships or material declines in performance are noted.
- ·Annual Meeting held virtually on May 28, 2026, at 10:00 AM PST via https://edge.media-server.com/mmc/go/apcx2026agm.
- ·Board has five directors divided into staggered Class I and Class II; nominees serve two-year terms until 2028 Annual Meeting.
- ·Proxy materials available at https://apptechcorp.com/leadership-governance and https://www.iproxydirect.com/apcx; Notice mailed on or about April 15, 2025.
14-04-2026
National Presto Industries, Inc. (NPK) issued a definitive proxy statement for its annual stockholder meeting on May 19, 2026, at 2:00 p.m. CDT in Eau Claire, WI, to elect directors Randy F. Lieble and Joseph G. Stienessen for three-year terms, ratify RSM US LLP as independent auditors for FY 2026, and approve named executive officer compensation on a non-binding advisory basis. As of the March 24, 2026 record date, 7,163,537 common shares were outstanding, with Maryjo Cohen beneficially owning 1,831,693 shares (25.6%), BlackRock, Inc. owning 831,156 shares (11.6%), and all officers and directors as a group owning 1,859,817 shares (26.0%). A Cohen family voting trust controls 1,669,664 shares, with Ms. Cohen as sole voting trustee.
- ·No delinquent Section 16(a) reports filed during FY 2025.
- ·Voting Trust Agreement terminates August 15, 2044, unless extended or terminated earlier.
- ·Record date: March 24, 2026; 2025 Annual Report available at www.gopresto.com/proxy/ or by phone 1-800-945-0199.
14-04-2026
Eos Energy Enterprises, Inc. (EOSE) has filed its DEF 14A Proxy Statement for the virtual Annual Meeting of Stockholders on June 3, 2026, at 10:00 a.m. ET, seeking approval for: (1) election of three Class III directors (Jeff Bornstein, Claude Demby, Nathaniel Fick); (2) ratification of Deloitte & Touche LLP as independent auditors for FY ending December 31, 2026; (3) advisory approval of named executive officer compensation; (4) amendment to increase authorized common stock from 600,000,000 to 800,000,000 shares; and (5) amendment to the Second Amended and Restated 2020 Incentive Plan. The Board recommends voting 'FOR' all proposals, with record date of April 13, 2026; separately, Series B Preferred Stock holders appoint three directors (Nick Robinson, Gregory Nixon, David Urban). No financial performance metrics or period-over-period comparisons are detailed in the filing.
- ·Record Date: April 13, 2026
- ·Virtual Meeting: www.virtualshareholdermeeting.com/EOSE2026
- ·Fiscal Year Reference: Ended December 31, 2025 (10-K)
- ·Preferred Stock Director Rights: Exclusive appointment of up to 3 directors by Series B holders
14-04-2026
NerdWallet, Inc. filed its definitive proxy statement (DEF 14A) for the 2026 Annual Meeting of Stockholders on May 21, 2026, at 10:00 a.m. PT virtually, seeking to elect four director nominees and ratify Deloitte & Touche LLP as independent auditors for the year ending December 31, 2026. The CEO letter highlights 2025 expansions into hands-on services like wealth management and debt consolidation, new performance marketing channels, organic channel momentum, vertical integrations, and the October 2024 acquisition of Next Door Lending LLC for mortgage brokerage. Record date is March 24, 2026; no financial metrics or performance declines are detailed in the filing.
- ·Annual Meeting held virtually at www.virtualshareholdermeeting.com/NRDS2026; pre-registration required with control number.
- ·Mailing of Notice of Internet Availability of Proxy Materials begins on or about April 14, 2026.
- ·Proposal 1: Election of 4 directors by plurality vote; Proposal 2: Auditor ratification by majority of voting power present.
- ·References 2025 Annual Report on Form 10-K for financial details.
14-04-2026
ADT Inc.'s 2026 Proxy Statement details the virtual Annual Meeting on May 27, 2026, for electing directors, an advisory vote on named executive officer compensation, and ratification of the independent auditor. The letter from CEO Jim DeVries highlights 2025 strategic progress including ADT+ expansion, Origin AI acquisition, and AI investments, alongside governance enhancements like board declassification, stockholder special meeting rights, and fully independent key committees, supported by over 12,000 professionals. No performance declines or flat metrics are mentioned.
- ·Annual Meeting: Wednesday, May 27, 2026, 8:30 a.m. EDT, virtual via live audio webcast
- ·Record Date: March 30, 2026
- ·Board composition: 8 independent directors, 3 Apollo designees, plus CEO
- ·Governance changes in 2025: board declassification, stockholder right to call special meetings, independent Audit, Compensation, and Nominating Committees
14-04-2026
Equity Residential's 2026 Proxy Statement highlights 2025 performance, including Normalized FFO per share of $3.99, up 2.6% YoY, same-store revenue growth of 2.6% and NOI growth of 2.2% (top-quartile among peers), alongside dispositions of $1.1B funding $636.8M acquisitions and $300M share repurchases. While expenses rose a modest 3.7% YoY, the company maintained a conservative balance sheet, issued $500M in debt, and returned $1.38B to shareholders via dividends and buybacks. Sustainability achievements included a 20.2% reduction in energy intensity, meeting 2030 goals early.
- ·Same store Turnover of 40.2% for full year 2025, lowest in company history.
- ·EPS of $2.94, FFO of $3.94 per share for full year 2025.
- ·Annual Meeting on June 18, 2026 at 8:00 a.m. Central Time, virtual at www.virtualshareholdermeeting.com/EQR2026; Record Date March 31, 2026.
- ·Weighted average share repurchase price of $62.03.
14-04-2026
California BanCorp's 2026 Annual Proxy Statement details corporate governance practices, including insider trading policies, anti-hedging policy, and board oversight of risks such as cybersecurity. In 2025, the Board held 18 meetings, the Audit and Risk Committee (ARC) met 13 times, and the Compensation, Nominating and Governance Committee (CNG) met 11 times, with all 12 directors attending at least 75% of meetings and the annual shareholder meeting. Non-employee director compensation includes a $110,000 annual retainer (half cash, half equity), with 2025 totals ranging from $36,667 (for retired director) to $134,003.
- ·All non-employee directors received 3,729 RSUs on May 21, 2025, vesting on May 21, 2026.
- ·Shareholder nomination notice must be provided no earlier than 120 days and no later than 90 days before the annual meeting date.
- ·Board held regular meetings twice a quarter in 2025, with additional special meetings as needed.
14-04-2026
Arbutus Biopharma Corporation's definitive proxy statement for its 2026 Annual General and Special Meeting on May 26, 2026, seeks shareholder approval for electing five director nominees, approving the 2026 Omnibus Share and Incentive Plan reserving 16,300,000 common shares, an advisory 'Say on Pay' vote on named executive officer compensation, and appointing Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026. The record date is March 30, 2026, with 196,939,679 common shares outstanding. No financial performance metrics or period-over-period comparisons are detailed in the proxy materials.
- ·Annual Meeting location: 700 W Georgia St., 25th Floor, Vancouver, BC Canada V7Y 1B3 at 10:00 a.m. Pacific Daylight Time
- ·Record date for voting: close of business on March 30, 2026
- ·Proxy materials and 2025 Annual Report on Form 10-K available online at www.ProxyVote.com, www.arbutusbio.com, www.sec.gov, and www.sedarplus.ca
14-04-2026
Myriad Genetics' 2026 proxy statement features CEO Samraat S. Raha's letter highlighting 2025 revenue of $824.5 million, positive adjusted EBITDA and EPS, MyRisk hereditary cancer test volume growth of 10% YoY, and GeneSight mental health test volumes up 8% in H2 after addressing H1 unfavorable events. The company outlined a new Cancer Care Continuum strategy with leadership additions like CCO Brian Donnelly and CFO Ben Wheeler, partnerships with PATHOMIQ and SOPHiA Genetics, and 2026 launches including AI-enhanced Prolaris and Precise MRD (entering $20B TAM). Achievements include 1.5 million tests delivered, NPS of 72.5, and Forbes Best Employer recognition with 84% Great Place to Work rating.
- ·Universal Plus Panel for Foresight® Carrier Screen covers 274 genes
- ·Prequel® Prenatal Screening available at eight weeks gestational age
- ·Precise MRD detects circulating tumor DNA to one part per million
- ·Precise MRD supported by more than 20 ongoing studies across multiple cancer types
- ·Precise MRD clinical testing launched for breast cancer in March 2026 with select customers
14-04-2026
Onity Group Inc. (ONIT) issued its DEF 14A Proxy Statement dated April 14, 2026, for the virtual 2026 Annual Meeting of Shareholders on May 19, 2026, at 9:00 a.m. EDT, soliciting votes on electing seven director nominees, ratifying Deloitte & Touche LLP as independent auditor for 2026, and an advisory 'Say-on-Pay' vote on named executive officer compensation. The record date is March 23, 2026, with proxies by default voting 'FOR' all proposals; the filing includes Pay vs. Performance disclosures for PEO and Non-PEO NEOs across 2021-2025 but no specific financial metrics are detailed.
- ·Virtual meeting access: www.virtualshareholdermeeting.com/ONIT2026
- ·Record Date: March 23, 2026
- ·Proxy materials first sent: April 14, 2026
- ·Company address: 1661 Worthington Road, Suite 100, West Palm Beach, Florida 33409
- ·Shareholder relations: shareholderrelations@onitygroup.com
14-04-2026
Customers Bancorp, Inc. filed its definitive proxy statement (DEF 14A) on April 14, 2026, for the virtual 2026 Annual Meeting of Shareholders on May 26, 2026, at 10:00 a.m. ET, where shareholders will vote on electing three Class III directors for three-year terms, ratifying Deloitte & Touche LLP as independent auditors for the fiscal year ending December 31, 2026, an advisory 'Say on Pay' vote on named executive officer compensation, and approving an amendment to the 2019 Stock Incentive Plan. The record date is April 1, 2026, with approximately 33,680,944 shares of Voting Common Stock outstanding. No financial performance metrics or period-over-period comparisons are detailed in the filing.
- ·Annual Meeting to be held virtually at www.meetnow.global/MK99JGA
- ·Proxy materials mailed on or about April 15, 2026
- ·Available online at www.envisionreports.com/CUBI and www.customersbank.com/investor-relations
14-04-2026
Strata Critical Medical, Inc. (formerly Blade Air Mobility, Inc.) has issued a proxy statement for its 2026 Annual Meeting of Stockholders on May 28, 2026, to elect two Class II directors (William A. Heyburn and Andrew Lauck) for terms until the 2029 Annual Meeting, ratify Deloitte & Touche LLP as independent auditors for the fiscal year ending December 31, 2026, and approve executive compensation on an advisory basis. Eric Affeldt will not stand for re-election and Susan Lyne is resigning effective at the meeting, reducing board continuity in Class II. Stockholders of record as of March 31, 2026, can vote virtually via www.virtualshareholdermeeting.com/SRTA2026.
- ·Annual Meeting is virtual only, starting at 9:00 a.m. Eastern Time, with online access from 8:45 a.m.
- ·Company sold its passenger business to Joby Aero, Inc. in August 2025 and rebranded from BLDE to SRTA.
- ·Board is divided into three classes with staggered three-year terms.
- ·Proxy materials first available on or about April 14, 2026.
14-04-2026
Cohen & Steers Income Opportunities REIT, Inc. has issued a proxy statement for its 2026 Annual Meeting of Stockholders, to be held virtually on June 25, 2026, at 9:00 a.m. New York time, seeking approval to elect five director nominees and ratify Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The record date is April 2, 2026, with 22,246,883 shares of Common Stock outstanding across various classes; the Board recommends voting 'FOR' both proposals.
- ·No Class T, Class S, Class D, Class M-I, or Class M-S shares outstanding as of Record Date.
- ·Voting deadline for Internet/telephone proxies: 11:59 p.m. New York time on June 24, 2026.
- ·Virtual meeting access: www.virtualshareholdermeeting.com/CNSREIT2026 (requires 16-digit control number).
- ·Proxy materials first mailed on or about April 14, 2026.
14-04-2026
Catalyst Bancorp, Inc. has issued a proxy statement for its Annual Meeting of Shareholders on May 19, 2026, at 8:00 a.m. CT in Opelousas, Louisiana, to elect two directors (Frederick R. Lafleur and Matthew L. Scruggins) for three-year terms expiring in 2029 and to ratify BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026. Shareholders of record as of March 30, 2026, when 4,058,297 shares of common stock were issued and outstanding, are entitled to vote; the Board recommends voting FOR both proposals. No other matters are anticipated.
- ·Proxy cards must be received by 11:59 p.m. ET on May 18, 2026; ESOP and 401(k) voting instructions by May 12, 2026.
- ·Directors elected by plurality vote; auditor ratification requires majority of votes cast.
- ·2025 Annual Report enclosed but not part of proxy solicitation.
14-04-2026
Socket Mobile, Inc. filed its DEF 14A Proxy Statement for the 2026 Annual Meeting of Stockholders, expected in June 2026, with a Record Date of April 6, 2026. The meeting includes Proposal 1: election of five directors (Charlie Bass, Kevin Mills, Bill Parnell, Ivan Lazarev, Lynn Zhao), as Felix Marx is not standing for re-election; Proposal 2: advisory vote on named executive officer compensation; and Proposal 3: ratification of Sadler, Gibb & Associates, LLC as independent auditors for the fiscal year ending December 31, 2026. As of the Record Date, 8,222,958 shares of Common Stock were outstanding, plus 733,194 shares subject to unvested restricted stock awards.
- ·Principal beneficial owners of more than 5% of Common Stock as of Record Date: Charlie Bass, Kevin Mills, Enrico Mills
- ·Deadline for stockholder proposals for inclusion in 2027 proxy statement: December 2, 2026
- ·Advance notice deadline for 2027 Annual Meeting nominations/proposals: February 15, 2027
- ·Rule 14a-19 proxy solicitation notice deadline for 2027: March 16, 2027
14-04-2026
Flowers Foods, Inc. (FLO) issued its DEF 14A proxy statement for the 2026 Annual Meeting on May 29, 2026, seeking approval for election of nine director-nominees (eight independent), advisory approval of named executive officer compensation, ratification of PricewaterhouseCoopers LLP as independent auditors, and approval of the 2026 Equity and Incentive Compensation Plan. Fiscal 2025 (53-week year) financial highlights include net sales of $5.256B and adjusted EBITDA of $535.2M, but GAAP diluted EPS was $0.40 and net income $83.8M, significantly below adjusted figures of $1.09 and $231.6M respectively, highlighting reliance on non-GAAP adjustments. The company outlines strategic priorities in team development, brand focus, margin improvement, and disciplined M&A, targeting long-term annual growth of 1-2% in net sales, 4-6% in adjusted EBITDA, and 7-9% in adjusted EPS (excluding acquisitions).
- ·Annual Meeting date: Thursday, May 29, 2026 at 11:30 a.m. Eastern Time via live webcast at www.virtualshareholdermeeting.com/FLO2026
- ·Record date: March 24, 2026
- ·Fiscal 2025 refers to the 53-week year ended January 3, 2026
- ·Average tenure of independent director-nominees: 6.2 years
- ·Average age of independent director-nominees: 61.4 years
- ·Added 6 new independent directors since beginning of 2020
14-04-2026
Bluerock Homes Trust, Inc., an externally managed REIT focused on residential properties in Sunbelt and Western U.S. markets, issued this DEF 14A proxy statement for its virtual annual stockholder meeting on June 10, 2026, at 11:00 a.m. ET. The record date is April 10, 2026, with 4,105,568 shares of Class A Common Stock and 8,489 shares of Class C Common Stock outstanding, deemed to represent 4,114,057 total voting shares. Stockholders are urged to vote promptly via proxy, internet, phone, or at the virtual meeting using www.virtualshareholdermeeting.com/BHM2026.
- ·The Company is an emerging growth company under the JOBS Act and will cease to be one on the earliest of specified events, including the last day of fiscal year 2027.
- ·Annual Meeting is completely virtual via live webcast with online check-in at 10:45 a.m. ET; access requires 12-digit control number.
- ·Proxy materials, including 2025 Annual Report on Form 10-K, available at http://www.bluerockhomes.com.
- ·Class C Common Stock entitles holders to up to 50 votes per share, limited by economic interests in the Operating Partnership.
14-04-2026
Broadwind, Inc. (BWEN) has issued a DEF 14A Proxy Statement for its 2026 Annual Meeting of Stockholders, to be held virtually on May 28, 2026, at 8:00 a.m. CDT, soliciting votes on electing five directors, an advisory vote to approve named executive officer compensation, and ratification of RSM US LLP as independent auditor for 2026. The record date is April 6, 2026, with 23,404,116 shares of Common Stock outstanding, entitling holders to one vote per share. Proxy materials are available online via www.bwen.com and www.sec.gov, with voting options by phone, internet, or mail.
- ·Quorum requires majority of voting power of outstanding shares
- ·Proposal 3 (auditor ratification) is routine; others may result in broker non-votes
- ·Internet voting closes at 11:59 p.m. ET on May 27, 2026
- ·Principal executive office: 3240 South Central Avenue, Cicero, Illinois 60804
14-04-2026
Franklin BSP Capital Corporation (FBCC) has issued a proxy statement for its 2026 Annual Meeting of Stockholders, to be held virtually on June 5, 2026 at 11:00 a.m. ET. Stockholders will vote on electing two directors for three-year terms expiring in 2029 and authorizing the Board to issue up to 25% of outstanding common stock below then-current NAV per share, which could have dilutive effects. As of the record date April 7, 2026, 138,924,652 common shares and 77,500 Series A preferred shares were outstanding, with preferred voting on an as-converted basis.
- ·Annual Meeting is completely virtual at www.virtualshareholdermeeting.com/FBCC2026; proxy voting instructions at www.proxyvote.com/FBCC.
- ·Preferred stock conversion rates: 64.98 (12/27/2021), 64.68 (4/7/2022), 65.53 (7/15/2022), 66.67 (11/23/2022), 66.01 (3/7/2023) shares of common stock per preferred share.
- ·Proxy deadline: 11:59 p.m. ET on June 4, 2026.
14-04-2026
Bandwidth Inc. (BAND) filed a DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders, to be held virtually on May 28, 2026, seeking approval to elect two Class III directors to serve until the 2029 annual meeting, ratify Ernst & Young LLP as independent auditors for fiscal year ending December 31, 2026, approve named executive officer compensation on an advisory basis, and vote on the frequency of future say-on-pay advisory votes. The record date is April 1, 2026, with 30,056,655 shares of Class A common stock (1 vote per share) and 1,958,027 shares of Class B common stock (10 votes per share) outstanding. No specific financial performance metrics or period-over-period comparisons are detailed in the provided filing content.
- ·Annual Meeting registration required at www.proxydocs.com/BAND before 9:30 a.m. ET on May 27, 2026
- ·Proxy materials Notice mailed on or about April 14, 2026
- ·Class A and Class B common stock vote as a single class; no cumulative voting for directors
14-04-2026
TrueBlue, Inc. issued its 2026 Proxy Statement for the virtual Annual Meeting on May 11, 2026, seeking shareholder approval for electing directors (8 of 9 nominees independent), advisory vote on executive compensation, amendment of the 2016 Omnibus Incentive Plan, and ratification of Deloitte & Touche LLP as auditor. The company reported $1.6B in 2025 revenue, $11.8M Adjusted EBITDA, repurchased 6.7M shares over five years reducing outstanding shares by 19%, connected 290K+ people to work, and served 50K+ clients while completing the acquisition of Healthcare Staffing Professionals, Inc. No declines or flat metrics were highlighted in the provided content.
- ·Record date for voting: March 23, 2026
- ·Fiscal year end: December 28, 2025
- ·Top 5 market position in U.S. industrial staffing with coverage in 50 states
- ·Served industries include Manufacturing & Logistics, Transportation, Energy & Industrial, and others
14-04-2026
Drugs Made In America Acquisition Corp., a SPAC, is holding an Extraordinary General Meeting on April 27, 2026, to vote on extending its business combination deadline from April 29, 2026, up to 12 one-month periods to April 29, 2027, conditional on sponsor deposits of the lesser of $300,000 or $0.04 per non-redeemed public share monthly into the $242M trust account. While the company has a non-binding LOI for a potential deal, there is no binding agreement and no assurance of completion even with the extension, risking full redemption and liquidation of public shares at ~$10.52 each if not approved or no deal by deadline. The board recommends approval but notes sponsor interests differ from public shareholders.
- ·Extraordinary General Meeting at 10:00 a.m. ET on April 27, 2026, in-person at Loeb & Loeb LLP offices or via teleconference (Meeting ID: 920 8650 7710; Passcode: 711212).
- ·Record Date: April 7, 2026; Termination Date: April 29, 2026; maximum Extended Date: April 29, 2027.
- ·Public shareholders may redeem shares regardless of vote; aggregate redemptions limited to 15% without company consent.
- ·Sponsor receives non-interest bearing promissory note for extension deposits, not repaid if no business combination unless funds outside trust available.
- ·Existing charter allows two 3-month extensions at $0.10 per public share, but board seeks additional time.
14-04-2026
Enveric Biosciences, Inc. (ENVB) filed a DEF 14A proxy statement for its Annual Meeting, seeking approval to elect six directors until the 2027 Annual Meeting, advisory vote on executive compensation, extend reverse stock split authority (1-for-5 to 1-for-50 ratio) previously approved in December 2025, increase authorized common shares from 100,000,000 to 5,000,000,000, ratify CBIZ CPAs P.C. as auditors for FY2026, and allow adjournment if needed. As of the March 30, 2026 record date, 1,887,535 shares of common stock were outstanding. These extensions provide Board flexibility for Nasdaq compliance and capital raising without immediate share issuance.
- ·Previous reverse stock split and authorized share increase approvals from December 11, 2025 special meeting expire December 11, 2026.
- ·Reverse stock split would not change authorized shares or proportional ownership, but aims to support Nasdaq listing compliance.
- ·Proxy holders: Joseph Tucker, Ph.D. and Kevin Coveney.
14-04-2026
Mattel's definitive proxy statement filed April 14, 2026, for the May 28, 2026 annual meeting, highlights 2025 full-year financial performance with gross billings comparable (flat) to 2024 and net sales declining 1% YoY, as International growth offset North America declines amid U.S. trade uncertainties. Vehicles category grew strongly while Challenger categories combined also grew. The company celebrated its 80th anniversary, emphasizing its mission in innovative play products.
- ·Annual stockholder meeting scheduled for May 28, 2026
- ·Fiscal year end: December 31
- ·Headquarters: 333 Continental Blvd, El Segundo, CA 90245
- ·Includes PEO and Non-PEO NEO compensation adjustments for years 2021-2025 (XBRL disclosures)
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 36 filings
🇺🇸 More from United States
View all →April 07, 2026
US Pre-Market SEC Filings Roundup — April 07, 2026
US Pre-Market SEC Filings Roundup
April 07, 2026
S&P 500 Consumer Staples Sector SEC Filings — April 07, 2026
S&P 500 Consumer Staples Sector SEC Filings
April 07, 2026
S&P 500 Financials Sector SEC Filings — April 07, 2026
S&P 500 Financials Sector SEC Filings
April 07, 2026
Nasdaq 100 Stocks SEC Filings — April 07, 2026
Nasdaq 100 Stocks SEC Filings